CVS Health stock: RBC trims target over separation costs
Published on 11/21/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey developments for CVS Health
- RBC Capital kept its Outperform rating after updating its model for the planned separation.
- The planned split into two public companies remains a central issue for investors.
- Expected separation-related cost drag is weighing on the analyst valuation framework.
RBC Capital lowered its price target for CVS Health on Monday, November 16, 2026, while keeping an Outperform rating. Investing.com reported that the target was cut to 108 US dollars from 113 US dollars.
The revision reflects RBC's updated financial model for CVS Health's planned separation transaction. The analyst incorporated initial assumptions for dis-synergies and expected cost drag, while leaving the prior multiple framework unchanged.
Separation remains the central issue
CVS Health plans to split into two public companies by the first half of 2028, according to the report. The separation gives investors a strategic catalyst but also puts execution costs and the future structure of the pharmacy business at the center of valuation discussions.
The analyst action followed CVS Health's third-quarter results and a stronger full-year outlook, but the target reduction shows that strategic restructuring costs remain an important counterweight in valuation work. RBC's continued Outperform stance indicates that the lower target did not change the firm's overall rating view.
CVS Health stock traded at 73.71 euros on Lang & Schwarz at 11:13 CET on Saturday, November 21, 2026.
CVS Health Corp.
- Company: CVS Health Corp.
- ISIN: US1266501006
- Ticker: CVS
- Primary exchange: NYSE
- Latest quoted price: 73.71 euros on Lang & Schwarz, Saturday, November 21, 2026, 11:13 CET
Investors can follow broader developments through Current market reports.
